Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT00798135
First received: November 24, 2008
Last updated: September 9, 2014
Last verified: September 2014
Results First Received: August 25, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Pharmacokinetics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Breast Neoplasms
Neoplasm Metastasis
Intervention: Drug: itraconazole

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Itraconazole oral itraconazole 200mg a day until disease progression or unacceptable toxicities.

Participant Flow:   Overall Study
    Itraconazole  
STARTED     13  
COMPLETED     0  
NOT COMPLETED     13  
Disease progression, relapse                 11  
Disease progression, refractory                 1  
Physician Decision                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Itraconazole oral itraconazole 200mg a day until disease progression or unacceptable toxicities.

Baseline Measures
    Itraconazole  
Number of Participants  
[units: participants]
  13  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     7  
>=65 years     6  
Age  
[units: Years]
Mean ± Standard Deviation
  59.8  ± 14.3  
Gender  
[units: participants]
 
Female     13  
Male     0  
Ethnicity (NIH/OMB)  
[units: participants]
 
Hispanic or Latino     0  
Not Hispanic or Latino     13  
Unknown or Not Reported     0  
Race (NIH/OMB)  
[units: participants]
 
American Indian or Alaska Native     0  
Asian     0  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     1  
White     12  
More than one race     0  
Unknown or Not Reported     0  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Pharmacokinetics (PK) of Oral Itraconazole   [ Time Frame: pre-dose at Weeks 2 and 4 ]

2.  Secondary:   Number of Patients With Adverse Events Grade 3 or 4 That Are Related to Study Treatment   [ Time Frame: up to 100 months ]

3.  Secondary:   Time to Progression.   [ Time Frame: up to 100 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Kathy Miller, MD
Organization: IndianaU
e-mail: kathmill@iupui.edu


No publications provided


Responsible Party: Indiana University
ClinicalTrials.gov Identifier: NCT00798135     History of Changes
Other Study ID Numbers: 0809-10; IUCRO-0239
Study First Received: November 24, 2008
Results First Received: August 25, 2014
Last Updated: September 9, 2014
Health Authority: United States: Institutional Review Board